|
FDA Lays Out Requirements for Initial Assessments of DMFs Under GDUFA
The FDA has outlined requirements that drugmakers submitting Type II active pharmaceutical ingredient (API) drug master files (DMF) must meet before the files are listed on the agency’s public website as available for reference to support an ANDA.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives